BIOGRAPHY

Dr. Deal obtained her Ph.D. in Experimental Medicine (Molecular Endocrinology) from McGill University (Supervisor, Dr. Harvey Guyda), and her M.D. degree from the Université de Montréal, followed by her U.S. and Canadian specialty certifications in Pediatrics and Pediatric Endocrinology and Metabolism with training at the Montreal Children’s Hospital (McGill), Sainte-Justine Hospital (Université de Montréal) and Stanford University in California (supervisor, Dr. Ron Rosenfeld). She is currently the Chief of Endocrinology and Diabetes at the Sainte-Justine Mother-Child University Hospital, where she has worked since 1992. She is a tenured Full Professor with the Department of Pediatrics at the Université de Montréal. Dr Deal has completed mandates as the President of the Canadian Society of Endocrinology and Metabolism (2007-11), as Council Member for the Growth Hormone Research Society (2009-12), as a member of the Steering Committee for the Endocrine Society (2011-14) and as a member and then treasurer (annual budget: 80 million $ CDN) of the Board of Directors for the Fonds de recherche en santé du Québec (FRSQ; 1999-2006). She currently sits on the Board of Directors for EVIDEM, a non-profit organization which promotes public health by developing efficient MCDA-based solutions to healthcare decision-making and priority setting, and she is on the Medical Review Board for the Canadian Center for Ethics in Sports. Her patient advocacy work includes the positions of board member and medical advisor to the Canadian Turner Syndrome Society (1999-2004), medical advisor to the Quebec Turner Association since 1994, and member of the medical board of Camp Carowanis for Diabetic Children (2003 to 2012). Dr. Deal’s involvement in education has included the position of Training Director for the Royal College program in Pediatric Endocrinology and Diabetes for the University of Montreal (2005-2013). She is currently the site leader for the pan-Canadian Child Health Clinical Scientist Training Program (CCHCSP). Over 25 clinical pediatric fellows and 20 adult endocrine fellows have passed through her clinic and laboratory, as well as undergraduate students, graduate students, medical students and pediatric residents that she has also had the chance to help mentor. She has been on many scientific organizing committees for several international meetings, including the International Congress of Endocrinology (2012, 2014), The Endocrine Society (2011-2014) and the Joint meeting of the Pediatric Endocrine Societies (2009, 2013) in addition to co-organising the Joint Meeting of the Pediatric Endocrine Societies in 2001 in Montreal. During the course of her career as an FRSQ Clinical Scientist, Dr. Deal’s research interests have included the genetics and the epigenetics of the growth hormone-insulin-like growth factor (GH-IGF) axis, the role of epigenetics in Turner Syndrome, the contribution of polymorphisms in IGFBP3, IGFBP1 and IGFI to normal biological variation and the SGA phenotype, as well as the role of various members of the GH-IGF axis in carcinogenesis. She has contributed to the elucidation of the molecular defects associated with a wide range of rare pediatric endocrine disorders including the recently described DICER1 Familial Cancer Syndrome and the primordial growth disorder Meier-Gorlin Syndrome, as well as participated in clinical studies aimed at ameliorating outcomes in endocrine diseases such as APECED, Prader-Willi Syndrome, congenital hypopituitarism and Turner Syndrome. She has experience in multicenter clinical trials (most recently phase 3 studies with long-acting GH and with anorexigens in PWS) and in clinical practice guideline development for several endocrine diagnoses. This work has led to over 150 published articles and over 160 invited national and international talks. She has also sat on several international scientific advisory boards, including the Lilly GeNeSIS study, has been invited to participate in her second NIH site review, and has served mandates on both the Québec FRQS and the Canadian CIHR grant review committees.